Tirzepatideinyowani mbiri mbiri agonist yeGIP uye GLP-1 receptors, yakatenderwa kudzora glycemic muvakuru vane Type 2 chirwere cheshuga pamwe nekutonga uremu kwenguva refu muvanhu vane body mass index (BMI) ≥30 kg/m², kana ≥27 kg/m² ine kanenge kamwe chete kunoenderana nehuremu comorbidity.
Kune chirwere cheshuga, inoderedza kutsanya uye postprandial glucose nekunonoka kubuda mudumbu, kuwedzera glucose-inotsamira insulin secretion, uye kudzvinyirira glucagon kusunungurwa, ine njodzi yakaderera ye hypoglycemia kana ichienzaniswa neyechinyakare insulin secretagogues. Mukugadzirisa kufutisa, zviito zvaro zviviri zvepakati uye zvemukati zvinoderedza kudya uye kuwedzera kushandiswa kwesimba. Miedzo yemakiriniki yakaratidza kuti mavhiki e52-72 ekurapa anogona kuwana avhareji yekuderedza uremu hwe15% -20%, ichiperekedzwa nekuvandudzwa kwechiuno chechiuno, BP, uye triglycerides.
Zviitiko zvinonyanya kushata zvinyoro kusvika pakati nepakati zviratidzo zvemudumbu, zvinowanzoitika mumavhiki mashoma ekutanga uye zvinodzikiswa nekukwira kwedosi zvishoma nezvishoma. Clinical initiation inokurudzirwa pasi pekuongororwa kwe endocrinologist kana uremu-management nyanzvi, nekuenderera mberi kwekutarisa kweglucose, uremu hwemuviri, uye renal basa. Pakazere, tirzepatide inopa humbowo-hwakavakirwa, hwakachengeteka, uye hwakasimba hwekurapa sarudzo kune varwere vanoda zvese glycemic uye uremu kudzora.
Nguva yekutumira: Aug-27-2025